52544-151 NDC - SILODOSIN

Drug Information

  • Product NDC: 52544-151
  • Proprietary Name:
  • Non Proprietary Name: silodosin
  • Active Ingredient(s): 4 mg/1 SILODOSIN
  • Administration Route(s):
  • Dosage Form(s): CAPSULE

Labeler Information

Field Name Field Value
Labeler Name: Actavis Pharma, Inc.
Product Type: DRUG FOR FURTHER PROCESSING
FDA Application Number:
Marketing Category: DRUG FOR FURTHER PROCESSING
Start Marketing Date:3/23/2009
End Marketing Date:3/31/2026

Package Information

No. Package Code Package Description Billing Unit
152544-151-0017937 CAPSULE in 1 DRUM (52544-151-00)
252544-151-1990 CAPSULE in 1 BOTTLE, UNIT-DOSE (52544-151-19)
352544-151-3030 CAPSULE in 1 BOTTLE, UNIT-DOSE (52544-151-30)EA

NDC Record

Field Name Field Value Definition
PRODUCT NDC52544-151The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
START MARKETING DATE3/23/2009This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE10/31/2020This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMEActavis Pharma, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
PRODUCT NDC52544-151The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
START MARKETING DATE3/23/2009This is the date that the labeler indicates was the start of its marketing of the drug product.
END MARKETING DATE3/31/2026This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
MARKETING CATEGORY NAMEDRUG FOR FURTHER PROCESSINGProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMEActavis Pharma, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.

Download Record

Download this NDC record record in Text format: Export

Download this NDC record record in Excel (CSV) format: Export

Download this NDC record record in XML format: Export

This page was last updated on: 7/25/2025